NCT00669903View on ClinicalTrials.gov

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Schizophrenia
Interventions
DRUG

AZD0328

DRUG

Placebo

Trial Locations (2)

Unknown

Research Center, Garden Grove

Research Center, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY